A carregar...
Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative colitis (UC). A range of 5-ASA preparations is available and Eudragit-S(®) coated modified release formulations of mesalamine, such as Asacol(®), remain among the most popular choices. We here review the current...
Na minha lista:
Main Authors: | , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Dove Medical Press
2009
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3108647/ https://ncbi.nlm.nih.gov/pubmed/21694838 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|